Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine
Patients who carry the diagnosis of Recurrent Respiratory Papillomatosis (RRP) will be asked
to participate in the study. These patients have been followed by the faculty investigator
for several years. Their disease state requires frequent interventions aimed at decreasing
the severity and symptomatology of their vocal fold papillomas. Patients will be given the
human papillomavirus quadrivalent vaccine and their clinical course will be followed over
the next 6 months. Patients will have a laryngoscopic examination prior to treatment to
establish their baseline disease state. They will have repeat laryngoscopic examinations at
the time of the first, second and third vaccine injections, which will be given 1 month
intervals for a total of 3 doses. They will have physical exam and laryngoscopic
examinations at 1 month intervals for the first 6 months after administration of the
vaccine. The severity of their clinical disease will be objectively measured using a
validated scale for RRP assessment, the Laryngoscopic and Clinical Assessment Scale (LCAS).
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Comparison of the pre-vaccine and post-vaccine RRP scoring assessments, intersurgical intervals, and annualized surgical rates.
12 months
Yes
Troy D Scheidt, MD
Principal Investigator
University of Missour-Columbia
United States: Institutional Review Board
1124197
NCT00829608
January 2009
June 2010
Name | Location |
---|---|
University of Missouri | Columbia, Missouri 65212 |